Subscribe to the 100% free rdnewsNOW daily newsletter!
clarification

Vaccine used in Alberta not linked to blood clot issue in Europe: Hinshaw

Mar 11, 2021 | 4:33 PM

Alberta’s chief medical officer of health says there is currently no indication that vaccination from some particular batches of AstraZeneca vaccine has caused blood clots among Albertans.

Dr. Deena Hinshaw said Thursday that the vaccine being used in Alberta is not linked to the issues being seen in Europe.

“We are currently using Covishield, the brand name of a vaccine produced by the Serum Institute of India that is considered equivalent to Astra Zeneca by Health Canada,” she said.

“Health Canada authorized these vaccines after independent and thorough scientific reviews for safety, efficacy and quality. And Canada has a robust surveillance system in place to detect rare occurrences following vaccination.”

She said Canadians can feel confident the review process for each vaccine was rigorous and systems are in place to monitor everything after authorization.

As well, Alberta has a strong adverse event surveillance system and any potential concerns will lead to more investigation by Alberta Health.

She also it is “important to note that these are extremely rare events in an area that is using a lot of vaccine.”

She also said that more than 11 million doses of AstraZeneca vaccine have been given in the United Kingdom with no indication blood clots have happened more often than in the general population.

Hinshaw encouraged all Albertans to book an appointment for vaccination when they are eligible.

As of 2:30 p.m. more than 23,000 Albertans have signed up for their Covishield AstraZeneca vaccine. The rollout is being done by years and starting tomorrow those born from 1957-60 will be able to book appointments online or by calling 811.

First Nations, Metis and Inuit people born from 1972-75 can book by calling 811.

(CHAT News Today)